Concepts (212)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 15 | 2025 | 419 | 3.380 |
Why?
|
| Osteosarcoma | 12 | 2024 | 253 | 2.300 |
Why?
|
| Sarcoma, Ewing | 4 | 2025 | 107 | 1.320 |
Why?
|
| Hematuria | 1 | 2025 | 55 | 0.920 |
Why?
|
| Antineoplastic Agents | 7 | 2025 | 1660 | 0.850 |
Why?
|
| Hypersplenism | 1 | 2020 | 2 | 0.710 |
Why?
|
| Desmoplastic Small Round Cell Tumor | 1 | 2020 | 10 | 0.700 |
Why?
|
| Disclosure | 1 | 2021 | 148 | 0.670 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2019 | 23 | 0.620 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2025 | 1214 | 0.620 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 221 | 0.600 |
Why?
|
| Neoplasms | 6 | 2025 | 2772 | 0.590 |
Why?
|
| Embolization, Therapeutic | 1 | 2020 | 222 | 0.580 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2018 | 12 | 0.580 |
Why?
|
| Acute Kidney Injury | 1 | 2025 | 636 | 0.570 |
Why?
|
| Retinal Neoplasms | 1 | 2018 | 100 | 0.530 |
Why?
|
| Wilms Tumor | 1 | 2018 | 113 | 0.530 |
Why?
|
| Lung Neoplasms | 4 | 2019 | 1645 | 0.530 |
Why?
|
| Hepatoblastoma | 1 | 2018 | 179 | 0.490 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2021 | 882 | 0.450 |
Why?
|
| Neuroblastoma | 1 | 2019 | 520 | 0.430 |
Why?
|
| RNA, Long Noncoding | 3 | 2022 | 211 | 0.430 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 433 | 0.430 |
Why?
|
| Ifosfamide | 2 | 2025 | 30 | 0.420 |
Why?
|
| Rhabdomyosarcoma | 3 | 2021 | 191 | 0.410 |
Why?
|
| Receptor, ErbB-2 | 3 | 2015 | 514 | 0.410 |
Why?
|
| T-Lymphocytes | 4 | 2017 | 1709 | 0.410 |
Why?
|
| Neoplasm Metastasis | 5 | 2024 | 665 | 0.400 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2025 | 827 | 0.390 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 1207 | 0.380 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 211 | 0.350 |
Why?
|
| Child | 18 | 2025 | 24374 | 0.340 |
Why?
|
| Cancer Survivors | 3 | 2025 | 202 | 0.330 |
Why?
|
| Neoplastic Stem Cells | 1 | 2011 | 291 | 0.320 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2022 | 365 | 0.300 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 1312 | 0.280 |
Why?
|
| Humans | 32 | 2025 | 124618 | 0.280 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2024 | 1895 | 0.260 |
Why?
|
| Immunotherapy | 3 | 2017 | 670 | 0.260 |
Why?
|
| Gene Expression Profiling | 2 | 2015 | 1702 | 0.250 |
Why?
|
| Anthracyclines | 2 | 2025 | 36 | 0.230 |
Why?
|
| Adolescent | 12 | 2025 | 19278 | 0.230 |
Why?
|
| Mice, SCID | 4 | 2019 | 568 | 0.230 |
Why?
|
| Methotrexate | 2 | 2019 | 341 | 0.220 |
Why?
|
| Mice, Inbred NOD | 3 | 2019 | 285 | 0.220 |
Why?
|
| MicroRNAs | 2 | 2023 | 837 | 0.200 |
Why?
|
| Tripartite Motif-Containing Protein 28 | 1 | 2022 | 16 | 0.200 |
Why?
|
| Proton Therapy | 1 | 2024 | 123 | 0.200 |
Why?
|
| Cardiovascular Diseases | 2 | 2025 | 1947 | 0.200 |
Why?
|
| Cell Line, Tumor | 5 | 2024 | 3339 | 0.190 |
Why?
|
| Sertoli-Leydig Cell Tumor | 1 | 2022 | 16 | 0.190 |
Why?
|
| Electron Transport Complex I | 1 | 2021 | 33 | 0.190 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 717 | 0.190 |
Why?
|
| Hematologic Neoplasms | 1 | 2025 | 284 | 0.190 |
Why?
|
| Stroke Volume | 2 | 2022 | 487 | 0.190 |
Why?
|
| Rothmund-Thomson Syndrome | 1 | 2021 | 47 | 0.190 |
Why?
|
| RecQ Helicases | 1 | 2021 | 62 | 0.190 |
Why?
|
| MyoD Protein | 1 | 2021 | 21 | 0.190 |
Why?
|
| Doxorubicin | 2 | 2020 | 289 | 0.180 |
Why?
|
| Ribonuclease III | 1 | 2022 | 89 | 0.180 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2022 | 121 | 0.180 |
Why?
|
| Acrylamides | 1 | 2020 | 17 | 0.180 |
Why?
|
| Ventricular Function, Left | 2 | 2022 | 506 | 0.170 |
Why?
|
| Uncertainty | 1 | 2021 | 98 | 0.170 |
Why?
|
| Atrial Function, Left | 1 | 2020 | 27 | 0.170 |
Why?
|
| p21-Activated Kinases | 1 | 2020 | 57 | 0.170 |
Why?
|
| Aminopyridines | 1 | 2020 | 55 | 0.170 |
Why?
|
| Etoposide | 1 | 2020 | 114 | 0.170 |
Why?
|
| Mice | 11 | 2024 | 17639 | 0.170 |
Why?
|
| Cell Proliferation | 6 | 2024 | 2287 | 0.170 |
Why?
|
| ras Proteins | 1 | 2020 | 137 | 0.170 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2021 | 122 | 0.160 |
Why?
|
| Echocardiography, Doppler | 1 | 2020 | 171 | 0.160 |
Why?
|
| Vincristine | 1 | 2020 | 191 | 0.160 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2019 | 40 | 0.160 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2020 | 126 | 0.160 |
Why?
|
| Epigenesis, Genetic | 1 | 2024 | 673 | 0.160 |
Why?
|
| Biomarkers, Tumor | 4 | 2020 | 1485 | 0.160 |
Why?
|
| Prognosis | 4 | 2025 | 4625 | 0.160 |
Why?
|
| Pyrroles | 1 | 2020 | 177 | 0.160 |
Why?
|
| Radiation Injuries | 1 | 2020 | 143 | 0.160 |
Why?
|
| beta Catenin | 1 | 2019 | 203 | 0.150 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2019 | 184 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 1140 | 0.150 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 418 | 0.150 |
Why?
|
| Pyrazoles | 1 | 2020 | 306 | 0.150 |
Why?
|
| Heart Atria | 1 | 2020 | 316 | 0.150 |
Why?
|
| Follow-Up Studies | 4 | 2025 | 5145 | 0.150 |
Why?
|
| Ovarian Neoplasms | 1 | 2022 | 418 | 0.140 |
Why?
|
| Cardiomyopathies | 1 | 2022 | 492 | 0.140 |
Why?
|
| Bone Marrow | 1 | 2019 | 324 | 0.140 |
Why?
|
| Infant | 4 | 2025 | 12468 | 0.140 |
Why?
|
| Bone and Bones | 1 | 2019 | 266 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2017 | 482 | 0.130 |
Why?
|
| Female | 14 | 2025 | 66495 | 0.130 |
Why?
|
| Neoplasm Staging | 3 | 2017 | 1248 | 0.130 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2017 | 158 | 0.130 |
Why?
|
| Animals | 11 | 2024 | 34088 | 0.130 |
Why?
|
| Sarcoma, Experimental | 1 | 2015 | 16 | 0.130 |
Why?
|
| Treatment Outcome | 6 | 2024 | 12324 | 0.120 |
Why?
|
| Male | 14 | 2025 | 61200 | 0.120 |
Why?
|
| Heart Diseases | 1 | 2020 | 490 | 0.120 |
Why?
|
| Receptors, Cell Surface | 1 | 2017 | 469 | 0.120 |
Why?
|
| Heart Transplantation | 1 | 2022 | 855 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1232 | 0.120 |
Why?
|
| Biopsy | 1 | 2019 | 1237 | 0.120 |
Why?
|
| Echocardiography | 1 | 2020 | 1052 | 0.120 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2015 | 152 | 0.120 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2017 | 235 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 197 | 0.110 |
Why?
|
| Parents | 1 | 2021 | 1015 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 3 | 2020 | 1062 | 0.110 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 669 | 0.110 |
Why?
|
| Heart-Assist Devices | 1 | 2022 | 1021 | 0.110 |
Why?
|
| Cardiotoxicity | 2 | 2025 | 33 | 0.100 |
Why?
|
| Young Adult | 5 | 2024 | 9014 | 0.100 |
Why?
|
| Receptor, EphA2 | 1 | 2012 | 29 | 0.100 |
Why?
|
| Sarcoma | 1 | 2015 | 183 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2015 | 1016 | 0.100 |
Why?
|
| Radiotherapy | 2 | 2025 | 133 | 0.100 |
Why?
|
| Apoptosis | 4 | 2020 | 1789 | 0.090 |
Why?
|
| Luminescent Measurements | 1 | 2011 | 57 | 0.090 |
Why?
|
| Organic Chemicals | 1 | 2011 | 59 | 0.090 |
Why?
|
| Predictive Value of Tests | 3 | 2022 | 2154 | 0.090 |
Why?
|
| Spheroids, Cellular | 1 | 2011 | 57 | 0.090 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2011 | 125 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 723 | 0.090 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 254 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 354 | 0.090 |
Why?
|
| Fluorescent Dyes | 1 | 2011 | 261 | 0.080 |
Why?
|
| Retrospective Studies | 6 | 2025 | 16317 | 0.080 |
Why?
|
| Pediatrics | 1 | 2018 | 1163 | 0.080 |
Why?
|
| HEK293 Cells | 1 | 2011 | 744 | 0.080 |
Why?
|
| Glioblastoma | 1 | 2012 | 327 | 0.080 |
Why?
|
| Heart Failure | 1 | 2022 | 2283 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 1089 | 0.080 |
Why?
|
| Adult | 4 | 2018 | 29440 | 0.080 |
Why?
|
| Transcriptome | 1 | 2015 | 952 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 1284 | 0.080 |
Why?
|
| Genetic Therapy | 1 | 2012 | 679 | 0.070 |
Why?
|
| Osteoblasts | 2 | 2021 | 148 | 0.070 |
Why?
|
| Child, Preschool | 4 | 2025 | 14009 | 0.060 |
Why?
|
| Mutation | 3 | 2022 | 5826 | 0.050 |
Why?
|
| Radiotherapy Dosage | 1 | 2024 | 183 | 0.050 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2023 | 22 | 0.050 |
Why?
|
| Risk Factors | 3 | 2025 | 10270 | 0.050 |
Why?
|
| American Heart Association | 1 | 2025 | 322 | 0.050 |
Why?
|
| Survival Rate | 2 | 2017 | 2044 | 0.050 |
Why?
|
| Cell Respiration | 1 | 2021 | 23 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2020 | 3281 | 0.050 |
Why?
|
| Oxadiazoles | 1 | 2021 | 25 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2021 | 85 | 0.050 |
Why?
|
| Oxidative Phosphorylation | 1 | 2021 | 107 | 0.050 |
Why?
|
| Chromatin | 1 | 2024 | 551 | 0.050 |
Why?
|
| Consensus | 1 | 2024 | 646 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 2876 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 2021 | 282 | 0.040 |
Why?
|
| Osteogenesis | 1 | 2021 | 154 | 0.040 |
Why?
|
| Quinolines | 1 | 2021 | 98 | 0.040 |
Why?
|
| Cellular Senescence | 1 | 2021 | 161 | 0.040 |
Why?
|
| Piperidines | 1 | 2021 | 204 | 0.040 |
Why?
|
| Imidazoles | 1 | 2021 | 194 | 0.040 |
Why?
|
| Systole | 1 | 2020 | 198 | 0.040 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2021 | 193 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 555 | 0.040 |
Why?
|
| Observer Variation | 1 | 2020 | 299 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2022 | 1322 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 442 | 0.040 |
Why?
|
| Cell Movement | 1 | 2020 | 836 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2021 | 997 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2019 | 579 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2020 | 542 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 273 | 0.030 |
Why?
|
| Caspase 2 | 1 | 2015 | 28 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 869 | 0.030 |
Why?
|
| Neuroectodermal Tumors | 1 | 2015 | 11 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2015 | 101 | 0.030 |
Why?
|
| Karyotyping | 1 | 2015 | 328 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2015 | 228 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 158 | 0.030 |
Why?
|
| Allografts | 1 | 2015 | 192 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2015 | 228 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2015 | 339 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2015 | 763 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 2818 | 0.030 |
Why?
|
| Homozygote | 1 | 2015 | 548 | 0.030 |
Why?
|
| Genomics | 1 | 2021 | 1503 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2024 | 6135 | 0.030 |
Why?
|
| ROC Curve | 1 | 2015 | 569 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 299 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2015 | 862 | 0.030 |
Why?
|
| K562 Cells | 1 | 2012 | 95 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2015 | 647 | 0.020 |
Why?
|
| Retroviridae | 1 | 2012 | 198 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 1032 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2012 | 227 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 3424 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2012 | 290 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2012 | 237 | 0.020 |
Why?
|
| Recurrence | 1 | 2015 | 1420 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2015 | 876 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2022 | 4505 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2012 | 502 | 0.020 |
Why?
|
| Time Factors | 1 | 2020 | 6293 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2015 | 2393 | 0.020 |
Why?
|
| United States | 1 | 2025 | 10891 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2012 | 940 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2015 | 3732 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 2091 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 4409 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 4352 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 3554 | 0.010 |
Why?
|